However, there was no significant difference in the levels of other atherogenic markers, such as C-reactive protein and sE-selectin, between the HFS and HF groups, suggesting that N-caffeoyltryptamine may specifically suppress MCP-1 expression in vitro and in vivo, possibly by inhibiting p38 MAP kinase. The gene discussed is CCL2; the disease is hydrops fetalis.